|
ATCC
a498 A498, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a-498/A-498/pmc07195723-39-21-31 Average 97 stars, based on 1 article reviews
a498 - by Bioz Stars,
2026-11
97/100 stars
|
Buy from Supplier |
|
CLS Cell Lines Service GmbH
a498 cells A498 Cells, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a-498/A498+Cells/pmc05356730-129-12-15 Average 92 stars, based on 1 article reviews
a498 cells - by Bioz Stars,
2026-11
92/100 stars
|
Buy from Supplier |
|
ATCC
a 498 A 498, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a-498/A-498%3B+Kidney+Carcinoma%3B+Human/pmc00018203-94-9-10 Average 95 stars, based on 1 article reviews
a 498 - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
DSMZ
human a498 kidney uroepithelial cell line Human A498 Kidney Uroepithelial Cell Line, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a-498/A-498/pm31361021-160-6-15 Average 94 stars, based on 1 article reviews
human a498 kidney uroepithelial cell line - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
BioResource International Inc
human rcc cell lines a-498 Human Rcc Cell Lines A 498, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a-498/human+ccrcc+cell+lines++786+o+and+a+498+/pmc04073433-329-0-24 Average 90 stars, based on 1 article reviews
human rcc cell lines a-498 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
JCRB Cell Bank
a498-luc A498 Luc, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a-498/a498+luc/pm33539630-35-0-17 Average 90 stars, based on 1 article reviews
a498-luc - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Korean Cell Line Bank
human renal cancer a498 cells ![]() Human Renal Cancer A498 Cells, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a-498/a498/pmc08566040-45-5-11 Average 90 stars, based on 1 article reviews
human renal cancer a498 cells - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Procell Inc
cell line a498 ![]() Cell Line A498, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a-498/a498/pm38890443-67-6-16 Average 90 stars, based on 1 article reviews
cell line a498 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
National Centre for Cell Science
a498 cells ![]() A498 Cells, supplied by National Centre for Cell Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a-498/a498+cells/pm28902490-161-1-8 Average 90 stars, based on 1 article reviews
a498 cells - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
iCell Bioscience Inc
a498 cell line ![]() A498 Cell Line, supplied by iCell Bioscience Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a-498/kirc+cell+lines+including+786+o++a498++caki+2+cells/pmc11850455-44-14-20 Average 90 stars, based on 1 article reviews
a498 cell line - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Inserm Transfert
ovcar ![]() Ovcar, supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a-498/renal+carcinoma+cell+line+a498/pmc02212908-118-8-19 Average 90 stars, based on 1 article reviews
ovcar - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Janvier Labs
a498 cells ![]() A498 Cells, supplied by Janvier Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a-498/a498+cells/pmc06956821-35-4-18 Average 90 stars, based on 1 article reviews
a498 cells - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Oxidative Medicine and Cellular Longevity
Article Title: Broussochalcone A Induces Apoptosis in Human Renal Cancer Cells via ROS Level Elevation and Activation of FOXO3 Signaling Pathway
doi: 10.1155/2021/2800706
Figure Lengend Snippet: Antiproliferative effects of BCA against renal cancer cell lines. Dose- and time-dependent effects of BCA (0, 5, 10, 20, and 40 μ M) against (a) A498 and (b) ACHN cells after treatment of BCA for 24, 48, and 72 h. The cell viability was detected using the MTT assay. Cell counting assay of (c) A498 and (d) ACHN cells treated with BCA (0, 5, 10, and 20 μ M) for 24, 48, and 72 h. Colony formation assay of (e) A498 and (g) ACHN cells treated with BCA (0, 5, 10, and 20 μ M) following 2 weeks. (f, h) The error bar represented the standard error. Significant differences between BCA treat and DMSO control groups are indicated as ∗ ( ∗ means p < 0.05, ∗∗ means p < 0.01, ∗∗∗ means p < 0.005).
Article Snippet: Human renal cancer A498 and
Techniques: MTT Assay, Cell Counting, Colony Assay, Control
Journal: Oxidative Medicine and Cellular Longevity
Article Title: Broussochalcone A Induces Apoptosis in Human Renal Cancer Cells via ROS Level Elevation and Activation of FOXO3 Signaling Pathway
doi: 10.1155/2021/2800706
Figure Lengend Snippet: G2/M cell cycle arrest in renal cancer A498 and ACHN cells. A498 and ACHN cells were treated with 0, 10, and 20 μ M of BCA for 48 h and stained with propidium iodide. Following that, the cells were measured with FACS. The cytogram results showed that the cell distribution and percentage of cells in each proportion of the cell cycle were represented for (a) A498 and (c) ACHN cells. Distribution of (b) A498 and (d) ACHN cells of each proportion of the cell cycle was shown after BCA treatment. Significant differences between BCA treat and DMSO control groups are indicated as ∗ ( ∗ means p < 0.05).
Article Snippet: Human renal cancer A498 and
Techniques: Staining, Control
Journal: Oxidative Medicine and Cellular Longevity
Article Title: Broussochalcone A Induces Apoptosis in Human Renal Cancer Cells via ROS Level Elevation and Activation of FOXO3 Signaling Pathway
doi: 10.1155/2021/2800706
Figure Lengend Snippet: Induction of apoptotic cell death in A498 and ACHN cells by the annexin V and PI doubling staining assay following 48 h of treatment with BCA (0, 10, and 20 μ M). (a, c) The percentages of apoptotic cells against A498 and ACHN cells are represented in cytogram. (b, d) Percentages of viable and apoptotic cells were indicated in bar graphs. The error bar represented the standard error. Significant differences between BCA treat and DMSO control groups are indicated as ∗ ( ∗ means p < 0.05).
Article Snippet: Human renal cancer A498 and
Techniques: Staining, Control
Journal: Oxidative Medicine and Cellular Longevity
Article Title: Broussochalcone A Induces Apoptosis in Human Renal Cancer Cells via ROS Level Elevation and Activation of FOXO3 Signaling Pathway
doi: 10.1155/2021/2800706
Figure Lengend Snippet: TUNEL assay results of A498 and ACHN cells treated with BCA (0, 10, and 20 μ M) for 48 h. DNA fragmentation was shown by fluorescence microscopy. (a, c) Blue fluorescence represents the nuclei stained using Hoechst 33342, and green fluorescence indicates the TUNEL-positive cells. (b, d) The bar graph showed that the percentages of TUNEL-positive cells after BCA treatment. The error bar represented the standard error. Significant differences between BCA treat and DMSO control groups are indicated as ∗ ( ∗ means p < 0.05).
Article Snippet: Human renal cancer A498 and
Techniques: TUNEL Assay, Fluorescence, Microscopy, Staining, Control
Journal: Oxidative Medicine and Cellular Longevity
Article Title: Broussochalcone A Induces Apoptosis in Human Renal Cancer Cells via ROS Level Elevation and Activation of FOXO3 Signaling Pathway
doi: 10.1155/2021/2800706
Figure Lengend Snippet: Western blot analysis of (a) A498 and (b) ACHN cells after treatment of BCA (0, 10, 20, and 40 μ M) for 24 h. The expression levels of specific proteins related to cell cycle arrest or apoptosis were detected by western blot analysis. β -actin was used as a loading control protein.
Article Snippet: Human renal cancer A498 and
Techniques: Western Blot, Expressing, Control
Journal: Oxidative Medicine and Cellular Longevity
Article Title: Broussochalcone A Induces Apoptosis in Human Renal Cancer Cells via ROS Level Elevation and Activation of FOXO3 Signaling Pathway
doi: 10.1155/2021/2800706
Figure Lengend Snippet: BCA induced the nuclear localization of FOXO3 protein and BCA-mediated apoptosis was dependent on FOXO3. Nuclear fraction western blot analysis results of (a) A498 and (b) ACHN cells treated with BCA (0, 10, 20, and 40 μ M) for 24 h. The expression levels of p27 and FOXO3 proteins in the cytoplasm and nucleus were investigated by performing western blot analysis. GAPDH, and Lamin A/C proteins were used for a gel-loading control for cytoplasmic and nuclear protein fractions, respectively. FOXO3 dependent apoptosis in renal cancer cells treated with BCA. Western blot results of (a) A498 and (b) ACHN cells transfected with control or FOXO3 siRNA and treated with BCA (0 and 10 μ M) for 24 h. β -actin was used as a loading control protein.
Article Snippet: Human renal cancer A498 and
Techniques: Western Blot, Expressing, Control, Transfection
Journal: Oxidative Medicine and Cellular Longevity
Article Title: Broussochalcone A Induces Apoptosis in Human Renal Cancer Cells via ROS Level Elevation and Activation of FOXO3 Signaling Pathway
doi: 10.1155/2021/2800706
Figure Lengend Snippet: Measurement of ROS intensity in (a, e) A498 and (c, g) ACHN cells. Measurement of intracellular ROS intensity in BCA-treated A498 and ACHN cells cotreated with NAC also measured. (b, d, f, and h) The bar graph indicated that the percentage of control of MFI according to treatment of BCA and NAC. (i) The cell viability of A498 and ACHN cells in response to control, BCA, NAC, and cotreatment of BCA and NAC. ∗ indicated the p value between the control and BCA treatment group, and # indicated the p value between NAC and NAC/BCA cotreatment group. Significant differences between BCA treat and DMSO control groups are indicated as ∗ ( ∗ means p < 0.05, ∗∗ means p < 0.01).
Article Snippet: Human renal cancer A498 and
Techniques: Control
Journal: Oxidative Medicine and Cellular Longevity
Article Title: Broussochalcone A Induces Apoptosis in Human Renal Cancer Cells via ROS Level Elevation and Activation of FOXO3 Signaling Pathway
doi: 10.1155/2021/2800706
Figure Lengend Snippet: Comet assay was performed to identify BCA induces DNA damage in (a) A498 and (b) ACHN cells. The cells were treated with BCA (0, 10, and 20 μ M) of 48 h. BCA-induced DNA damage was investigated using a comet assay. As shown, the length of comet tail dose-dependently enhanced in response to (0, 10, and 20 μ M) BCA treatment. (c, d) The bar graph indicated the length of comet tail increased significantly. Significant differences between BCA treat and DMSO control groups are indicated as ∗ ( ∗ means p < 0.05).
Article Snippet: Human renal cancer A498 and
Techniques: Single Cell Gel Electrophoresis, Control
Journal: Theranostics
Article Title: The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor
doi: 10.7150/thno.38346
Figure Lengend Snippet: 786-O and A498 cells present different sensitivities to ERLO . (A) 786-O cells were treated with increasing concentrations of ERLO. The percentage of live and dead cells is indicated. *p<0.05; **p<0.01. (B) A498 cells were treated with increasing concentrations of ERLO. The percentage of live and dead cells is indicated. * p < 0.05; *** p < 0.001. (C) 786-O or A498 cells were treated with increasing concentrations of ERLO. EGF levels were evaluated in cell supernatants by ELISA. *** p < 0.001. (D) 786-O or A498 cells were treated with increasing concentrations of ERLO and were evaluated for the presence of total and active form of EGF receptor (EGFR/pEGFR), HER3, the total and active form of ERK (ERK/pERK) and the active form of AKT (pAKT) by immuno-blotting. HSP90 is shown as a loading control. (E) 786-O or A498 cells were treated with increasing concentrations of ERLO. VEGF levels were evaluated in cell supernatants by ELISA. *** p < 0.001. (F) 786-O or A498 cells were treated with increasing concentrations of ERLO. CXCL8 levels were evaluated in cell supernatants by ELISA. ** p < 0.01; *** p < 0.001.
Article Snippet: Five million 786-O or
Techniques: Enzyme-linked Immunosorbent Assay, Control
Journal: Theranostics
Article Title: The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor
doi: 10.7150/thno.38346
Figure Lengend Snippet: The role of the BVZ/IFN and ERLO combination on RCC xenograft tumor growth . (A) 5.10 6 cells 786-O cells were subcutaneously injected into nude mice. Seven days after injections all mice developed tumors. 31 days after cell injection (start treatment), mice were treated twice a week with control or ERLO (E, 50 mg/kg) or BVZ (B, 7.5 mg/kg) plus IFN (I, 9MIU) plus or minus ERLO (50 mg/kg). The tumor volume is presented as the means ± s.d. ( n = 10). Statistical differences to the untreated mice are shown: *p <0.05; *** p<0.001. (B) Same experiment as described in a but using A498 cells. * p < 0.05; ** p< 0.01; *** p< 0.001. * p < 0.05; *** p < 0.001. (C) Images of the 786-O tumors at the end of the experiments. (D) Images of A498 tumors at the end of the experiment.
Article Snippet: Five million 786-O or
Techniques: Injection, Control
Journal: Theranostics
Article Title: The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor
doi: 10.7150/thno.38346
Figure Lengend Snippet: The BVZ/IFN/ERLO combination decreased the tumor blood vessel density and prevented/inhibited the development of lymphatic vessels. The tumor vasculature in each experimental group was detected by immuno-staining for CD31 (endothelial cells, green) and α-SMA i (pericytes, red); (A) 786-O cell model; (C) A498 cell model. LYVE-1 immuno-staining (green) shows lymphatic endothelial cells. Lymphatic vessels with lumens (L) are indicated. (B) 786-O model; (D) A498 model. Tumor sections were counterstained with 40,6-diamidino-2-phenylindole (DAPI) (nucleus, blue). (E) The intra-tumor amount of hemoglobin (Hg), a global read out of the blood supply, is given for both model systems and for the different experimental conditions.
Article Snippet: Five million 786-O or
Techniques: Immunostaining
Journal: Theranostics
Article Title: The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor
doi: 10.7150/thno.38346
Figure Lengend Snippet: The capacity to proliferate and the sensitivity to ERLO of cells from experimental tumors. (A) The capacity to proliferate of 786-O cells isolated from three independent tumors from each group was tested using the MTT assay (C cells from untreated mice; B+I; cells from BVZ/IFN-treated mice; B+I+E; cells from BVZ/IFN/ERLO-treated mice) in the absence (-) or presence (+) of ERLO. (B) The proliferative capacity of A498 cells isolated from three independent tumors for each group in the absence (-) or presence of ERLO was tested using MTT assays. For both cell types, results are presented as the mean fold increase ± s.d. Statistical differences in the fold increase of tumor cells isolated from control mice were taken as reference values. * p < 0.05; ** p < 0.01; *** p < 0.001. (C) Representative 786-O cells from the four experimental groups were tested for the presence of the total and active form of EGFR (EGFR/pEGFR) in the absence (-) or presence (+) of ERLO (10 µM). HSP90 is shown as a loading control. Quantification of the relative level of EGFR (EGFR/HSP90) and pEGFR (pEGFR/EGFR) is shown. The reference values (100%) correspond to the levels of EGFR and pEGFR in cells of tumors derived from untreated mice in the absence of ERLO. (D) Equivalent experiments as described in c for the A498 model.
Article Snippet: Five million 786-O or
Techniques: Isolation, MTT Assay, Control, Derivative Assay
Journal: Theranostics
Article Title: The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor
doi: 10.7150/thno.38346
Figure Lengend Snippet: The presence of a silent mutation in the kinase domain of EGFR is indicative of ERLO efficacy . (A) Sequence chromatogram analysis of the EGFR coding region of genomic DNA obtained from RCC4, 786-O and A498 cells. (B) The IC50 for ERLO of the different primary cells wild-type (WT) heterozygous (HET) or homozygous (HOM) for the G 2618 A mutation was tested by MTT assays. * p < 0.05; *** p < 0.001. (C) Equivalent experiments as described in (B) for AZD3759 compound. (D) In vitro transcription and translation of two independent wild-type (WT1, WT2) and mutated (Mut1, Mut2) EGFR expression plasmids. Upper panel: equal amounts of DNA were used for in vitro reactions, and the quality of the plasmids was verified on agarose gels colored with ethidium bromide. Lower panel: proteins resulting from the in vitro transcription/translation reaction were analyzed by immuno-blotting. (E) 200 ng of two independent expression vectors carrying wild-type (WT1, WT2) and mutated (Mut1, Mut2) EGFR expression plasmids were transfected into HEK293 and total protein lysates were analyzed by immune-blotting. Comparison between samples was performed after the calculation of the transfection efficiency. HSP90 is shown as a loading control.
Article Snippet: Five million 786-O or
Techniques: Mutagenesis, Sequencing, In Vitro, Expressing, Transfection, Comparison, Control